Roughly 82 percent of Americans support requiring Medicare and insurance companies to cover the Alzheimer's treatments.

This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are ...

A year out from Leqembi’s approval for Alzheimer’s disease (AD), ongoing research coupled with artificial intelligence is ...

On November 2, the Cenla Walk to End Alzheimer’s Association held its annual walk at Fort Randolph in Pineville.

The Alzheimer's disease drug Kisunla will face major reimbursement challenges in the U.K. after the cost-effectiveness ...

If you'd like to learn more or get involved, the Dallas Walk to End Alzheimer's starts Saturday morning at 8:30 at Dallas ...

Eisai has argued that maintenance dosing with Leqembi will prolong treatment benefits by targeting protofibrils, a toxic form of beta-amyloid.

Eisai (ESAIY) completes BLA submissions for an injectable version of its Biogen (BIIB)-partered Alzheimer's drug Leqembi in ...

Biogen's Q3 earnings report shows flat growth but highlights its value for risk-tolerant investors in CNS disease treatment.

Q3 2024 Earnings Call Transcript October 30, 2024 Biogen Inc. misses on earnings expectations. Reported EPS is $ EPS, expectations were $3.77. Operator: Good morning. My name is Cynthia, and I will be ...

TD Cowen analyst Phil Nadeau maintained a Buy rating on Biogen (BIIB – Research Report) yesterday and set a price target of $275.00. Phil ...

It’s just another earnings week in the life of pharmaceutical CEOs, with blockbuster expectations running up against cruel ...